<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02154854</url>
  </required_header>
  <id_info>
    <org_study_id>PHAO2011/YL/ADEQUATE-A</org_study_id>
    <secondary_id>2011-003184-29</secondary_id>
    <nct_id>NCT02154854</nct_id>
  </id_info>
  <brief_title>Prospective Study to Measure Vascular Parameters (Ancillary Study of ADEQUATE)</brief_title>
  <acronym>ADEQUATEartère</acronym>
  <official_title>Effect of Advagraf on Arterial Stiffness and on Vascular Fibrosis Plasma Markers on de Novo Renal Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare parallel-group effects between 4 months and 12 months
      post-transplantation 2 values of target residual concentrations of Advagraf on vascular
      parameters in de novo renal transplant patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aorta stiffness at one year post-tranplantation</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate the aorta stiffness at 1 year post-renal transplantation and its evolution in patients who received a half reduction of their daily dose of Advagraf ® 4 months after transplantation compared with patients whose dose has not been divided.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate peripheral and central blood pressures, the impact of reflected pressure waves and coupling cardiocirculatory (on the functional plan) and evaluate endothelial activation, factors promoting the vascular fibrosis and oxidant stress level (on biological plan) at 1 year post-renal transplantation and their evolution in patients who received a hal reduction of their daily dose Advagraf ® to four months of the transplant when compared with patients whose dose was not divided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial activation at one year post-tranplantation</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate peripheral and central blood pressures, the impact of reflected pressure waves and coupling cardiocirculatory (on the functional plan) and evaluate endothelial activation, factors promoting the vascular fibrosis and oxidant stress level (on biological plan) at 1 year post-renal transplantation and their evolution in patients who received a hal reduction of their daily dose Advagraf ® to four months of the transplant when compared with patients whose dose was not divided.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>De Novo Transplant Disease</condition>
  <arm_group>
    <arm_group_label>Group A - tacrolimus half-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immunosuppressive strategy with 50 % reduction of Advagraf® daily dose at M4 (randomization) and unchanged MMF dose. Targeted tacrolimus trough level are to be higher than 3 ng/mL . If the dose is not in adequation with the dispensable units, the prescribed dose will be the closest higher dose.
Drug: Tacrolimus targeted half-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B - tacrolimus unchanged dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immunosuppressive strategy will remain identical after randomization (M4): unchanged Advagraf® and MMF doses. Targeted tacrolimus trough level are to be between 7 and 12 ng/mL Drug: Tacrolimus targeted plain dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus targeted half-dose</intervention_name>
    <arm_group_label>Group A - tacrolimus half-dose</arm_group_label>
    <other_name>Advagraf®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus targeted plain dose</intervention_name>
    <arm_group_label>Group B - tacrolimus unchanged dose</arm_group_label>
    <other_name>Advagraf®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 et 70 years

          -  Patient accepting to give a written informed consent

          -  Recipients of a first renal allograft (deceased or living, non HLA identical donor
             with compatible ABO blood type)

          -  Randomized in the ADEQUATE study

          -  Patients must have at J112 +/- 3 days a stable renal function (MDRD 4) with an absence
             of DSA since transplantation.

          -  Negative T cross-match in cytotoxicity

          -  Tolerate a daily dose of MMF at 1g

        Exclusion Criteria:

          -  Acute rejection during the first months

          -  Existence of a BK infection since M3

          -  Proteinuria/reatininuria ratio &gt; 1g/g since M3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robinson JOANNIDES</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de ROUEN</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robinson JOANNIDES</last_name>
    <email>Robinson.Joannides@chu-rouen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mélissa DELHOMMEAU</last_name>
    <email>m.delhommeau@chu-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-François WESTEEL</last_name>
      <email>westeel.pierre-francois@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-François WESTEEL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François SUBRA</last_name>
      <email>JFSubra@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno HURAULT DE LIGNY</last_name>
      <email>huraultdeligny-b@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno HURAULT DE LIGNY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Elisabeth HENG</last_name>
    </contact>
    <investigator>
      <last_name>Anne-Elisabeth HENG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HEGP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric THERVET</last_name>
      <email>eric.thervet@egp.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Eric THERVET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe LEGENDRE</last_name>
      <email>christophe.legendre@nck.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe LEGENDRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile VIGNEAU</last_name>
      <email>cecile.vigneau@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Cécile VIGNEAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle ETIENNE</last_name>
      <email>isabelle.etienne@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle ETIENNE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno MOULIN</last_name>
      <email>moulin@unistra.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno MOULIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel ROSTAING</last_name>
      <email>rostaing.l@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Lionel ROSTAING</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvon LEBRANCHU</last_name>
      <email>yvon.lebranchu@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Yvon LEBRANCHU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2014</study_first_submitted>
  <study_first_submitted_qc>May 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2014</study_first_posted>
  <last_update_submitted>May 30, 2014</last_update_submitted>
  <last_update_submitted_qc>May 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal</keyword>
  <keyword>Transplantation</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Arterial stiffness</keyword>
  <keyword>Vascular fibrose plasma markers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

